collection
https://read.qxmd.com/read/33935943/agitation-and-dementia-prevention-and-treatment-strategies-in-acute-and-chronic-conditions
#1
REVIEW
Claudia Carrarini, Mirella Russo, Fedele Dono, Filomena Barbone, Marianna G Rispoli, Laura Ferri, Martina Di Pietro, Anna Digiovanni, Paola Ajdinaj, Rino Speranza, Alberto Granzotto, Valerio Frazzini, Astrid Thomas, Andrea Pilotto, Alessandro Padovani, Marco Onofrj, Stefano L Sensi, Laura Bonanni
Agitation is a behavioral syndrome characterized by increased, often undirected, motor activity, restlessness, aggressiveness, and emotional distress. According to several observations, agitation prevalence ranges from 30 to 50% in Alzheimer's disease, 30% in dementia with Lewy bodies, 40% in frontotemporal dementia, and 40% in vascular dementia (VaD). With an overall prevalence of about 30%, agitation is the third most common neuropsychiatric symptoms (NPS) in dementia, after apathy and depression, and it is even more frequent (80%) in residents of nursing homes...
2021: Frontiers in Neurology
https://read.qxmd.com/read/33933206/tocilizumab-in-patients-admitted-to-hospital-with-covid-19-recovery-a-randomised-controlled-open-label-platform-trial
#2
RANDOMIZED CONTROLLED TRIAL
(no author information available yet)
BACKGROUND: In this study, we aimed to evaluate the effects of tocilizumab in adult patients admitted to hospital with COVID-19 with both hypoxia and systemic inflammation. METHODS: This randomised, controlled, open-label, platform trial (Randomised Evaluation of COVID-19 Therapy [RECOVERY]), is assessing several possible treatments in patients hospitalised with COVID-19 in the UK. Those trial participants with hypoxia (oxygen saturation <92% on air or requiring oxygen therapy) and evidence of systemic inflammation (C-reactive protein ≥75 mg/L) were eligible for random assignment in a 1:1 ratio to usual standard of care alone versus usual standard of care plus tocilizumab at a dose of 400 mg-800 mg (depending on weight) given intravenously...
May 1, 2021: Lancet
https://read.qxmd.com/read/33999276/fluid-induced-harm-in-the-hospital-look-beyond-volume-and-start-considering-sodium-from-physiology-towards-recommendations-for-daily-practice-in-hospitalized-adults
#3
REVIEW
Niels Van Regenmortel, Lynn Moers, Thomas Langer, Ella Roelant, Tim De Weerdt, Pietro Caironi, Manu L N G Malbrain, Paul Elbers, Tim Van den Wyngaert, Philippe G Jorens
PURPOSE: Iatrogenic fluid overload is a potential side effect of intravenous fluid therapy in the hospital. Little attention has been paid to sodium administration as a separate cause of harm. With this narrative review, we aim to substantiate the hypothesis that a considerable amount of fluid-induced harm is caused not only by fluid volume, but also by the sodium that is administered to hospitalized patients. METHODS: We show how a regular dietary sodium intake is easily surpassed by the substantial amounts of sodium that are administered during typical hospital stays...
May 17, 2021: Annals of Intensive Care
https://read.qxmd.com/read/33046850/myocarditis-and-inflammatory-cardiomyopathy-current-evidence-and-future-directions
#4
REVIEW
Carsten Tschöpe, Enrico Ammirati, Biykem Bozkurt, Alida L P Caforio, Leslie T Cooper, Stephan B Felix, Joshua M Hare, Bettina Heidecker, Stephane Heymans, Norbert Hübner, Sebastian Kelle, Karin Klingel, Henrike Maatz, Abdul S Parwani, Frank Spillmann, Randall C Starling, Hiroyuki Tsutsui, Petar Seferovic, Sophie Van Linthout
Inflammatory cardiomyopathy, characterized by inflammatory cell infiltration into the myocardium and a high risk of deteriorating cardiac function, has a heterogeneous aetiology. Inflammatory cardiomyopathy is predominantly mediated by viral infection, but can also be induced by bacterial, protozoal or fungal infections as well as a wide variety of toxic substances and drugs and systemic immune-mediated diseases. Despite extensive research, inflammatory cardiomyopathy complicated by left ventricular dysfunction, heart failure or arrhythmia is associated with a poor prognosis...
March 2021: Nature Reviews. Cardiology
https://read.qxmd.com/read/32651579/extrapulmonary-manifestations-of-covid-19
#5
REVIEW
Aakriti Gupta, Mahesh V Madhavan, Kartik Sehgal, Nandini Nair, Shiwani Mahajan, Tejasav S Sehrawat, Behnood Bikdeli, Neha Ahluwalia, John C Ausiello, Elaine Y Wan, Daniel E Freedberg, Ajay J Kirtane, Sahil A Parikh, Mathew S Maurer, Anna S Nordvig, Domenico Accili, Joan M Bathon, Sumit Mohan, Kenneth A Bauer, Martin B Leon, Harlan M Krumholz, Nir Uriel, Mandeep R Mehra, Mitchell S V Elkind, Gregg W Stone, Allan Schwartz, David D Ho, John P Bilezikian, Donald W Landry
Although COVID-19 is most well known for causing substantial respiratory pathology, it can also result in several extrapulmonary manifestations. These conditions include thrombotic complications, myocardial dysfunction and arrhythmia, acute coronary syndromes, acute kidney injury, gastrointestinal symptoms, hepatocellular injury, hyperglycemia and ketosis, neurologic illnesses, ocular symptoms, and dermatologic complications. Given that ACE2, the entry receptor for the causative coronavirus SARS-CoV-2, is expressed in multiple extrapulmonary tissues, direct viral tissue damage is a plausible mechanism of injury...
July 2020: Nature Medicine
https://read.qxmd.com/read/32039404/beta-blockers-in-cirrhosis-evidence-based-indications%C3%A2-and%C3%A2-limitations
#6
REVIEW
Susana G Rodrigues, Yuly P Mendoza, Jaime Bosch
Non-selective beta-blockers (NSBBs) are the mainstay of treatment for portal hypertension in the setting of liver cirrhosis. Randomised controlled trials demonstrated their efficacy in preventing initial variceal bleeding and subsequent rebleeding. Recent evidence indicates that NSBBs could prevent liver decompensation in patients with compensated cirrhosis. Despite solid data favouring NSBB use in cirrhosis, some studies have highlighted relevant safety issues in patients with end-stage liver disease, particularly with refractory ascites and infection...
February 2020: JHEP reports: innovation in hepatology
https://read.qxmd.com/read/32019685/systemic-autoinflammatory-diseases
#7
REVIEW
Julie Krainer, Sandra Siebenhandl, Andreas Weinhäusel
Systemic autoinflammatory diseases (SAIDs) are a growing group of disorders caused by a dysregulation of the innate immune system leading to episodes of systemic inflammation. In 1997, MEFV was the first gene identified as disease causing for Familial Mediterranean Fever, the most common hereditary SAID. In most cases, autoinflammatory diseases have a strong genetic background with mutations in single genes. Since 1997 more than 30 new genes associated with autoinflammatory diseases have been identified, affecting different parts of the innate immune system...
May 2020: Journal of Autoimmunity
https://read.qxmd.com/read/32102926/albumin-in-decompensated-cirrhosis-new-concepts-and-perspectives
#8
REVIEW
Mauro Bernardi, Paolo Angeli, Joan Claria, Richard Moreau, Pere Gines, Rajiv Jalan, Paolo Caraceni, Javier Fernandez, Alexander L Gerbes, Alastair J O'Brien, Jonel Trebicka, Thierry Thevenot, Vicente Arroyo
The pathophysiological background of decompensated cirrhosis is characterised by a systemic proinflammatory and pro-oxidant milieu that plays a major role in the development of multiorgan dysfunction. Such abnormality is mainly due to the systemic spread of bacteria and/or bacterial products from the gut and danger-associated molecular patterns from the diseased liver triggering the release of proinflammatory mediators by activating immune cells. The exacerbation of these processes underlies the development of acute-on-chronic liver failure...
June 2020: Gut
https://read.qxmd.com/read/32054610/management-of-acute-ischemic-stroke
#9
REVIEW
Michael S Phipps, Carolyn A Cronin
Stroke is the leading cause of long term disability in developed countries and one of the top causes of mortality worldwide. The past decade has seen substantial advances in the diagnostic and treatment options available to minimize the impact of acute ischemic stroke. The key first step in stroke care is early identification of patients with stroke and triage to centers capable of delivering the appropriate treatment, as fast as possible. Here, we review the data supporting pre-hospital and emergency stroke care, including use of emergency medical services protocols for identification of patients with stroke, intravenous thrombolysis in acute ischemic stroke including updates to recommended patient eligibility criteria and treatment time windows, and advanced imaging techniques with automated interpretation to identify patients with large areas of brain at risk but without large completed infarcts who are likely to benefit from endovascular thrombectomy in extended time windows from symptom onset...
February 13, 2020: BMJ: British Medical Journal
https://read.qxmd.com/read/31990655/sepsis-and-septic-shock-guideline-based-management
#10
REVIEW
Siddharth Dugar, Chirag Choudhary, Abhijit Duggal
Sepsis is a life-threatening organ dysfunction that results from the body's response to infection. It requires prompt recognition, appropriate antibiotics, careful hemodynamic support, and control of the source of infection. With the trend in management moving away from protocolized care in favor of appropriate usual care, an understanding of sepsis physiology and best practice guidelines is critical.
January 2020: Cleveland Clinic Journal of Medicine
https://read.qxmd.com/read/31791953/management-of-severe-acute-pancreatitis
#11
REVIEW
O Joe Hines, Stephen J Pandol
The risks, measurements of severity, and management of severe acute pancreatitis and its complications have evolved rapidly over the past decade. Evidence suggests that initial goal directed therapy, nutritional support, and vigilance for pancreatic complications are best practice. Patients can develop pancreatic fluid collections including acute pancreatic fluid collections, pancreatic pseudocysts, acute necrotic collections, and walled-off necrosis. Several randomized controlled trials and cohort studies have recently highlighted the advantage of managing these conditions with a progressive approach, with initial draining for infection followed by less invasive techniques...
December 2, 2019: BMJ: British Medical Journal
https://read.qxmd.com/read/31764986/clinical-review-on-triglycerides
#12
REVIEW
Ulrich Laufs, Klaus G Parhofer, Henry N Ginsberg, Robert A Hegele
Hypertriglyceridaemia is a common clinical problem. Epidemiologic and genetic studies have established that triglyceride-rich lipoproteins (TRL) and their remnants as important contributors to ASCVD while severe hypertriglyceridaemia raises risk of pancreatitis. While low-density lipoprotein is the primary treatment target for lipid lowering therapy, secondary targets that reflect the contribution of TRL such as apoB and non-HDL-C are recommended in the current guidelines. Reduction of severely elevated triglycerides is important to avert or reduce the risk of pancreatitis...
January 1, 2020: European Heart Journal
https://read.qxmd.com/read/31662037/guidelines-for-the-early-management-of-patients-with-acute-ischemic-stroke-2019-update-to-the-2018-guidelines-for-the-early-management-of-acute-ischemic-stroke-a-guideline-for-healthcare-professionals-from-the-american-heart-association-american-stroke-association
#13
JOURNAL ARTICLE
William J Powers, Alejandro A Rabinstein, Teri Ackerson, Opeolu M Adeoye, Nicholas C Bambakidis, Kyra Becker, José Biller, Michael Brown, Bart M Demaerschalk, Brian Hoh, Edward C Jauch, Chelsea S Kidwell, Thabele M Leslie-Mazwi, Bruce Ovbiagele, Phillip A Scott, Kevin N Sheth, Andrew M Southerland, Deborah V Summers, David L Tirschwell
Background and Purpose- The purpose of these guidelines is to provide an up-to-date comprehensive set of recommendations in a single document for clinicians caring for adult patients with acute arterial ischemic stroke. The intended audiences are prehospital care providers, physicians, allied health professionals, and hospital administrators. These guidelines supersede the 2013 Acute Ischemic Stroke (AIS) Guidelines and are an update of the 2018 AIS Guidelines. Methods- Members of the writing group were appointed by the American Heart Association (AHA) Stroke Council's Scientific Statements Oversight Committee, representing various areas of medical expertise...
October 30, 2019: Stroke; a Journal of Cerebral Circulation
https://read.qxmd.com/read/30794136/aspiration-pneumonia-in-older-adults
#14
REVIEW
Alexander Makhnevich, Kenneth H Feldhamer, Charles L Kast, Liron Sinvani
Aspiration pneumonia refers to an infection of the lung parenchyma in an individual that has inhaled a bolus of endogenous flora that overwhelms the natural defenses of the respiratory system. While there are not universally agreed upon criteria, the diagnosis can be made in patients with the appropriate risk factors and clinical scenario, in addition to a radiographic or an ultrasonographic image of pneumonia in the typical dependent lung segment. Treatment options for aspiration pneumonia vary based on the site of acquisition (community-acquired aspiration pneumonia [CAAP] versus healthcare-associated aspiration pneumonia [HCAAP]), the risk for multidrug-resistant (MDR) organisms, and severity of illness...
July 1, 2019: Journal of Hospital Medicine: An Official Publication of the Society of Hospital Medicine
https://read.qxmd.com/read/31358311/anca-associated-vasculitis-core-curriculum-2020
#15
REVIEW
Duvuru Geetha, J Ashley Jefferson
Antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis (AAV) is a group of disorders characterized by inflammation and destruction of small- and medium-sized blood vessels and the presence of circulating ANCA. Clinical disease phenotypes include granulomatosis with polyangiitis, microscopic polyangiitis, eosinophilic granulomatosis with polyangiitis, and renal-limited vasculitis. Serologic classification of AAV into proteinase 3-ANCA disease and myeloperoxidase-ANCA disease correlates with a number of disease characteristics...
July 26, 2019: American Journal of Kidney Diseases
https://read.qxmd.com/read/31302175/news-in-pathophysiology-definition-and-classification-of-hepatorenal-syndrome-a-step-beyond-the-international-club-of-ascites-ica-consensus-document
#16
REVIEW
Paolo Angeli, Guadalupe Garcia-Tsao, Mitra K Nadim, Chirag R Parikh
Renal dysfunction is a common, life-threatening complication occurring in patients with liver disease. Hepatorenal syndrome (HRS) has been defined as a purely "functional" type of renal failure that often occurs in patients with cirrhosis in the setting of marked abnormalities in arterial circulation, as well as overactivity of the endogenous vasoactive systems.4,5 In 2007, the International Club of Ascites (ICA) classified HRS into types 1 and 2 (HRS-1 and HRS-2).5 HRS-1 is characterised by a rapid deterioration of renal function that often occurs because of a precipitating event, while HRS-2 is a moderate and stable or slowly progressive renal dysfunction that often occurs without an obvious precipitant...
October 2019: Journal of Hepatology
https://read.qxmd.com/read/31217796/heart-failure-with-preserved-ejection-fraction-in-the-elderly-pathophysiology-diagnostic-and-therapeutic-approach
#17
REVIEW
Ernesto Ruiz Duque, Alexandros Briasoulis, Paulino A Alvarez
Heart failure with preserved ejection fraction (HFpEF) is a clinical syndrome characterized by symptoms and sings of heart failure with elevated left ventricular filling pressures at rest or during exercise. It is the most common type of heart failure in the elderly and its prevalence increases with age and is higher in females at any given age. HFpEF is frequently accompanied of comorbid conditions such as diabetes mellitus, obesity, atrial fibrillation and renal dysfunction. The diagnosis relies in the integration of clinical information, laboratory data and interpretation of cardiac imaging and hemodynamic findings at rest and during exercise...
May 2019: Journal of Geriatric Cardiology: JGC
https://read.qxmd.com/read/31223468/adrenal-crisis-prevention-and-management-in-adult-patients
#18
REVIEW
Rosemary Dineen, Christopher J Thompson, Mark Sherlock
Adrenal crisis is an acute life-threatening emergency contributing to the excess mortality that is reported in patients with adrenal insufficiency. The incidence of adrenal crisis is estimated to be 8 per 100 patient years in patients with adrenal insufficiency. Patients with adrenal crisis present systemically unwell with nonspecific signs and symptoms often leading to misdiagnosis and delayed treatment. An adrenal crisis may be the first presentation of adrenal insufficiency or can occur in patients who have been established on glucocorticoid replacement therapy...
2019: Therapeutic Advances in Endocrinology and Metabolism
https://read.qxmd.com/read/31270110/2018-update-of-the-eular-recommendations-for-the-management-of-large-vessel-vasculitis
#19
JOURNAL ARTICLE
Bernhard Hellmich, Ana Agueda, Sara Monti, Frank Buttgereit, Hubert de Boysson, Elisabeth Brouwer, Rebecca Cassie, Maria C Cid, Bhaskar Dasgupta, Christian Dejaco, Gulen Hatemi, Nicole Hollinger, Alfred Mahr, Susan P Mollan, Chetan Mukhtyar, Cristina Ponte, Carlo Salvarani, Rajappa Sivakumar, Xinping Tian, Gunnar Tomasson, Carl Turesson, Wolfgang Schmidt, Peter M Villiger, Richard Watts, Chris Young, Raashid Ahmed Luqmani
BACKGROUND: Since the publication of the European League Against Rheumatism (EULAR) recommendations for the management of large vessel vasculitis (LVV) in 2009, several relevant randomised clinical trials and cohort analyses have been published, which have the potential to change clinical care and therefore supporting the need to update the original recommendations. METHODS: Using EULAR standardised operating procedures for EULAR-endorsed recommendations, the EULAR task force undertook a systematic literature review and sought opinion from 20 experts from 13 countries...
January 2020: Annals of the Rheumatic Diseases
https://read.qxmd.com/read/31179786/efficacy-of-ceftriaxone-1-g-daily-versus-2-g-daily-for-the-treatment-of-community-acquired-pneumonia-a-systematic-review-with-meta-analysis
#20
COMPARATIVE STUDY
João Paulo Telles, Juliette Cieslinski, Juliano Gasparetto, Felipe Francisco Tuon
Introduction : Ceftriaxone has been recommended as a first-line treatment for various infections; however, the doses for pneumonia have not been a consensus in randomized clinical trials. To compare ceftriaxone 1 g daily efficacy to other ceftriaxone dosing regimens in community-acquired pneumonia. Area covered : We performed a systematic review and meta-analysis on PubMed, Web of Science, Scopus, and LILACS. Randomized controlled trials of ceftriaxone in community-acquired pneumonia were included. Outcomes included clinical cure in modified intention-to-treatment, clinically and microbiologically evaluable patients...
July 2019: Expert Review of Anti-infective Therapy
label_collection
label_collection
6770
1
2
2019-07-02 12:06:27
Fetch more papers »
Fetching more papers... Fetching...
Remove bar
Read by QxMD icon Read
×

Save your favorite articles in one place with a free QxMD account.

×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"

We want to hear from doctors like you!

Take a second to answer a survey question.